chronic lymphocytic leukaemia

Showing 15 posts of 15 posts found.


Six-year follow-up data shows Imbruvica’s benefit in high-risk chronic lymphocytic leukaemia

December 7, 2020
Research and Development, Sales and Marketing Janssen, chronic lymphocytic leukaemia, imbruvica

Janssen has revealed multiple pooled data analyses for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib) in the first-line treatment …


Strong four-year follow-up data revealed for AbbVie’s venetoclax combo in chronic lymphocytic leukaemia

December 9, 2019
Research and Development, Sales and Marketing ASH 2019, AbbVie, chronic lymphocytic leukaemia, pharma, venetoclax

AbbVie used the platform of the American Society of Hematology (ASH) conference to present four-year follow-up analysis data on venetoclax …


Janssen chalks up two more indications in Europe for Imbruvica combo therapies

August 14, 2019
Research and Development, Sales and Marketing Europe, Janssen, chronic lymphocytic leukaemia, imbruvica, pharma

Janssen’s has secured a label expansion from the European Commission for its Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica (ibrutinib), approving …


AstraZeneca’s Calquence shows strength in most common adult leukaemia

June 6, 2019
Research and Development AstraZeneca, Calquence, chronic lymphocytic leukaemia, pharma

AstraZeneca has unveiled new Phase 3 data for Calquence (acalabrutinib) in treatment-naïve chronic lymphocytic leukaemia, showing that the drug met …


Lowered price wins NICE approval for Janssen leukaemia treatment

November 25, 2016
Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica

After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …

Roche’s MabThera gets European approval to treat chronic lymphocytic leukaemia

May 31, 2016
Manufacturing and Production Roche, chronic lymphocytic leukaemia, drug approval, regulation

Swiss drugmaker Roche (SIX: ROG) on Tuesday said the European Commission (EC) has approved the subcutaneous (SC) formulation of its …


Arzerra approved by US FDA for leukaemia

January 20, 2016
Research and Development, Sales and Marketing Afrezza, CLL, FDA, Genmab, Novartis, chronic lymphocytic leukaemia, ofatumumab, sBLA, supplementary biologics license application

The FDA has signed-off a supplemental Biologics License Application (sBLA), meaning Arzerra is approved for extended treatment of patients who …

AZ building

AstraZeneca in $5bn Acerta buyout talks

December 14, 2015
Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …

Abbvie and Roche report success in Phase II leukaemia trial

August 13, 2015
Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax

AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …


EMA approvals for rival blood cancer drugs

July 27, 2014
Research and Development, Sales and Marketing CLL, Gilead, Janssen, chronic lymphocytic leukaemia, imbruvica, zydelig

Gilead and Janssen are set to face off in Europe after the CHMP recommended both of their rival blood cancer …


Biogen gets CHMP thumbs up

May 27, 2014
Sales and Marketing Biogen, CHMP, Gazyvaro (obinutuzumab), Nuwiq, Octapharma, Orphan, Roche, chronic lymphocytic leukaemia, plegridy

Biogen Idec is celebrating after the Committee for Medicinal Products for Human Use (CHMP) gave its multiple sclerosis drug Plegridy …

Leukaemia drug fast-tracked by NICE

January 6, 2011
Sales and Marketing Bendamustine, Levact, NICE, Napp, chronic lymphocytic leukaemia, leukaemia

A treatment for patients with the most common form of leukaemia has been fast tracked by NICE because of strong …

Roche’s MabThera successor shows phase II promise

December 6, 2010
Research and Development, Sales and Marketing GA101, Genentech, GlycArt, MabThera, Roche, blood cancer, chronic lymphocytic leukaemia

The cancer drug Roche is developing as a second-generation successor to its blockbuster MabThera has shown promising results in a …

Latest content